AI assistant
UroGen Pharma Ltd. — Director's Dealing 2020
Dec 4, 2020
32312_dirs_2020-12-04_cb8903b7-e878-4280-bce1-b5c1ec603058.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-12-04
Reporting Person: Barrett Elizabeth A. (Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-04 | Ordinary Shares | M | 61652 | $0.00 | Acquired | 219117 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-04 | Restricted Stock Units | $ | M | 61652 | Disposed | Ordinary Shares (61652) | Direct |
Footnotes
F1: Represents the settlement of restricted stock units that vested from June 3, 2020 through December 3, 2020 through the issuance of ordinary shares.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F3: The reporting person was granted restricted stock units ("RSUs") on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter.